Sector
PharmaceuticalsOpen
₹89Prev. Close
₹86Turnover(Lac.)
₹2.04Day's High
₹89Day's Low
₹85.552 Week's High
₹104.7552 Week's Low
₹56Book Value
₹34.32Face Value
₹10Mkt Cap (₹ Cr.)
26.59P/E
35.71EPS
2.49Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 6.93 | 6.18 | 5.61 | 4.8 |
Net Worth | 9.92 | 9.17 | 8.6 | 7.79 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 13.94 | 14.83 | 6.84 | 6.43 |
yoy growth (%) | -5.95 | 116.75 | 6.26 | -9.32 |
Raw materials | -10.28 | -11.44 | -4.73 | -3.97 |
As % of sales | 73.74 | 77.16 | 69.16 | 61.68 |
Employee costs | -1.09 | -1.09 | -0.79 | -0.69 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 1.05 | 0.71 | 0.32 | 0.25 |
Depreciation | -0.14 | -0.17 | -0.13 | -0.13 |
Tax paid | -0.22 | -0.16 | -0.07 | -0.07 |
Working capital | 2.9 | -1.04 | -0.26 | -1.4 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -5.95 | 116.75 | 6.26 | -9.32 |
Op profit growth | 20.26 | 92.91 | 9.73 | 31.17 |
EBIT growth | 45.07 | 71.67 | 44.5 | 21.42 |
Net profit growth | 51.63 | 120.78 | 35.8 | 33.01 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,817.6 | 158.19 | 4,36,103.12 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,783.75 | 83.58 | 1,53,540.39 | 518 | 0.52 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.4 | 59.91 | 1,20,073.47 | 634.43 | 0 | 2,529.74 | 334.18 |
Cipla Ltd CIPLA | 1,475.9 | 28.16 | 1,19,195.76 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,401.2 | 70.36 | 1,15,106.89 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Jagdish Agrawal
Non Executive Director
Abha Agrawal
Director
Arvind Sapkal
Company Sec. & Compli. Officer
Srushti Pandya
Independent Director
Dhwani Jaypalsinh Solanki
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ishita Drugs & Industries Ltd
Summary
Ishita Drugs & Industries Limited was incorporated in Feb.92 by Jagdish Agarwal. The Company is engaged in the manufacture of various Activa Pharma Ingredients, drug intermediates, fine chemicals and excipient. It has a state-of-art manufacturing facility, in terms of reaction capabilities, quality control and environmental safety. The plant has been designed and constructed to meet GMP norms.The genesis of the Ishita Group in 1992 was the result of the entrepreneurial spirit of Mr. Jagdish Agrawal, who set up a reactive dye manufacturing unit in Ahmedabad. Buoyed by the growth of its first Venture, the Group made its maiden foray in the pharma sector in 1981 by setting up a small Bulk drugs plant at Surendranagar in Gujarat, to cater to the need of Pharma industry for Quality Products. The Bulk Drugs Industry at that point of time was highly dependent on costly imports and the growth was not achievable. The Company gradually formed a vertically integrated industry chain covering Drug Intermediates, Active Pharma Ingredients (APIs), excipients and finished dosage forms. The Group has 3 manufacturing facilities located in Gujarat, 2 for APIs and drug intermediates (at Ahmedabad and Surendranagar) and 1 for finished pharmaceutical formulations (at Mehsana).Thereafter, the Company set up a project to manufacture bulk drugs at Sanand, in the Ahmedabad district of Gujarat with an installed capacity of 408 tpa. Commercial production commenced in Jan.95. It established an in-house R
Read More
The Ishita Drugs & Industries Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹88.92 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ishita Drugs & Industries Ltd is ₹26.59 Cr. as of 24 Dec ‘24
The PE and PB ratios of Ishita Drugs & Industries Ltd is 35.71 and 2.59 as of 24 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Ishita Drugs & Industries Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ishita Drugs & Industries Ltd is ₹56 and ₹104.75 as of 24 Dec ‘24
Ishita Drugs & Industries Ltd's CAGR for 5 Years at 49.62%, 3 Years at 30.08%, 1 Year at 24.69%, 6 Month at 29.66%, 3 Month at 15.71% and 1 Month at 3.32%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice